Barrett's esophagus

New England Journal of Medicine

Volumn 361, Issue 26, 2009, Pages 2548-2556

  Sharma, Prateek ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; CONFOCAL LASER MICROSCOPY; DIAGNOSTIC ACCURACY; DISEASE SURVEILLANCE; ENDOSCOPIC MUCOSAL RESECTION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; MALE; NARROW BAND IMAGING; OBESITY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; ADENOCARCINOMA; ALGORITHM; ESOPHAGOSCOPY; ESOPHAGUS; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; MIDDLE AGED; MUCOSA; PATHOLOGY; REVIEW;

ADENOCARCINOMA; ALGORITHMS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; OBESITY; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 73549083853     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0902173     Document Type: Article

References (47)

1. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30.
2. Pohl H, Welch HG. The role of over-diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
4. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7.
5. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
6. Kubo A, Levin TR, Block G, et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009;136:806-15.
7. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:1-10.
8. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006;63:570-80.
9. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
10. Society for Surgery of the Alimentary Tract. SSAT patient care guidelines: management of Barrett's esophagus. J Gastrointest Surg 2007;11:1213-5.
11. Lagergren J, Bergstrom R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
12. Kahrilas PJ. Gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7.
13. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-9.
14. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol 2009;104:1356-62.
15. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
16. Watson A, Heading RC, Shepherd NA. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus: a report of the Working Party of the British Society of Gastroenterology. London: British Society of Gastroenterology, August 2005.
17. Boyer J, Laugier R, Chemali M, et al. French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's esophagus. Endoscopy 2007;39:840-2.
18. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
19. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
20. Wani S, Mathur S, Sharma P. How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin Gastroenterol Hepatol 2009;7:27-32.
21. Wani S, Falk GW, Sampliner RE, et al. Low-grade dysplasia is a poor marker for cancer progression in patients with Barrett's esophagus: preliminary results from a large, multi-center, cohort study. Gastroenterology 2009;136:A592. abstract.
22. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
23. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008;67:394-8.
24. Abela JE, Going JJ, Mackenzie JF, McKernan M, O'Mahoney S, Stuart RC. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008;103:850-5.
25. Wolfsen HC, Crook JE, Krishna M, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus. Gastroenterology 2008;135:24-31.
26. Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 2006;4:979-87.
27. Sharma P, Bansal A, Hawes R, et al. Detection of metaplasia and neoplasia in patients with Barrett's esophagus using high-definition white light endoscopy versus narrow band imaging: a prospective, multi-center, randomized, crossover trial. Gastrointest Endosc 2009;69:AB135. abstract.
28. Attwood SE, Lundell L, Hatlebakk JG, et al. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008;12:1646-54.
29. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83.
30. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180:387-91.
31. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
32. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003;98:2390-4.
33. Wani S, Sayana H, Sharma P. Endoscopic eradication of Barrett's esophagus. Gastrointest Endosc 2009 October 29 (Epub ahead of print).
34. Larghi A, Lightdale CJ, Memeo L, Bhagat G, Okpara N, Rotterdam H. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 2005;62:16-23.
35. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy. Ann Surg 1996;224:66-71.
36. Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008;6:159-64.
37. Oberg S, Johansson J, Wenner J, Walther B. Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Ann Surg 2002;235:338-45.
38. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9.
39. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98.
40. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8.
41. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
42. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-6.
43. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
44. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009;181:161-9.
45. Fitzgerald RC. Complex diseases in gastroenterology and hepatology: GERD, Barrett's, and esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:529-37.
46. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
47. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.